AMAG Pharma misses by $0.11, misses on revs; reaffirms FY13 revs guidance (AMAG) 16.55 : Reports Q4 (Dec) loss of $0.17 per share, $0.11 worse than the Capital IQ Consensus Estimate of ($0.06); revenues rose 41.9% year/year to $21.14 mln vs the $22.95 mln consensus. Co reaffirms guidance for FY13, sees FY13 revs of $73-77 mln vs. $77.56 mln Capital IQ Consensus Estimate.
- Net U.S. Feraheme product sales for the quarter ended December 31, 2012 were $14.4 mln, as compared to $12.8 mln of net U.S. Feraheme product sales for the same period in 2011.
- Net U.S. Feraheme product sales for the year ended December 31, 2012 were $58.3 mln, as compared to $52.1 mln for 2011.
Guidance Metrics:- Feraheme U.S. net product sales of between $63 mln and $67 mln
- Revenue from royalties, ex-U.S. product sales and milestones of ~$10 mln.